We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 12.50
Ask: 13.50
Change: 5.575 (75.08%)
Spread: 1.00 (8.00%)
Open: 9.65
High: 13.50
Low: 9.65
Prev. Close: 7.425
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

14 Apr 2023 07:00

RNS Number : 1808W
Carclo plc
14 April 2023
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

14 April 2023

 

Carclo plc

 

("Carclo" or the "Group")

 

Full Year Trading Update

 

Carclo, a preferred and trusted partner of global customers, providing high-precision critical components to the life sciences, aerospace, optics, and technology industries, today provides an update on trading for the financial year ended 31 March 2023 ("FY 2023").

During FY 2023, the Company encountered multiple significant challenges, including the dissolution of a major manufacturing contract, the adverse effects of rising input costs on margins, and increasing interest rates. In response to this altered landscape, the Board shifted the Group's strategy to focus on operational excellence and cash generation. Although the final quarter of FY 2023 has shown early signs of the new strategy's benefits, the overall full-year profit performance is anticipated to be below the previous year. As a result of the new focus on cash generation, the Group expects to deliver an improvement in net debt compared to the position at the half year, whilst having continued to make significant pension deficit repair contributions. The suppressed Manufacturing Solutions margins and reduced Design & Engineering activity within our Carclo Technical Plastics (CTP) business have only been partially counterbalanced by increased manufacturing volumes in CTP and a robust performance from our Aerospace division.

Redefined Strategy

During the latter half of FY2023 it became clear that the cash-intensive top-line growth strategy was unsustainable in the current economic climate. As a result, the Board has refocused the Group's strategy on margin expansion through operational excellence and balance sheet strengthening via cash generation. Our investment priorities now lie in supporting existing projects and continuous improvement with a swift return on investment. While we have already begun implementing this new strategy and there is still much to accomplish, we are witnessing early positive indications of enhanced margins and cash generation as FY2023 concludes.

 

Banking Arrangements

The Board continues to work with its lending bank, HSBC, to ensure that there is appropriate ongoing financial support for the business as it implements the new strategy. HSBC remain supportive and the Group successfully reached an agreement with them to reset the interest cover covenant for 31 March 2023. Discussions are continuing with HSBC regarding the setting of appropriate covenants for the forthcoming financial year.

 

Carclo Technical Plastics (CTP)

The CTP division achieved a robust revenue performance, despite facing significant headwinds during the year. Activity in the Design & Engineering segment reduced from the very high level of the prior year, but remained above historical norms. The Manufacturing Solutions segment delivered significant revenue growth, primarily from our existing customers in the life sciences sector, demonstrating our ability to grow organically in our chosen markets.

 

However, significant margin challenges offset this revenue growth, particularly the unprecedented increase in input costs, including soaring energy prices. While we have been able to pass on some of the higher costs to customers, the time delay in doing so has caused a significant drop in operating margins during the year. The effect of the lower margins was only partially mitigated by increased manufacturing volumes and we therefore expect the divisional underlying operating profit to be materially lower than the prior year.

 

We previously announced the dissolution of a significant manufacturing contract and are engaged in ongoing discussions with the customer to reach a commercial agreement for this contract.

 

Our current focus is on margin recovery through operational efficiency and optimisation. We have begun our factory specialisation journey in the EMEA region, with our UK facility concentrating on long production runs and our Czech facility focusing on short and medium-run products, prioritising flexibility and rapid changeovers. We are now implementing this factory specialisation strategy in the US. Our Chinese and Indian operations demonstrate strong growth potential and enhance our global presence. We expect a steady recovery in operating margins in the near term as our new strategy starts to yield results.

 

Aerospace

Our Aerospace division is witnessing a robust recovery as the aviation industry rebounds, with sales approaching pre-COVID levels. The division's unique market position ensures margin resilience amid inflation, and we expect solid profits and operating cash flow for FY2023. Our focus lies in expanding sales within existing markets and creating high-precision, safety-critical solutions for specialised sectors.

 

Governance

The Board is dedicated to maintaining high governance standards and regulatory compliance. We have restructured the Board, separating the roles of Non-Executive Chairman and Chief Executive, in line with the Corporate Governance Code. Rachel Amey's recent appointment as a Non-Executive Director strengthens the Board, as her financial expertise will help ensure adherence to best practice in financial controls and governance.

 

Outlook

We remain dedicated to providing sustainable earnings growth and value creation for our stakeholders, despite the persistent challenges caused by inflationary pressures. Our new strategy emphasises cash generation, stability, operational excellence, and optimising our global footprint. We are implementing measures to enhance manufacturing and supply chain efficiency while minimising environmental impact. Our endeavours to optimise our global footprint will enable us to serve our customers better, support growth in key markets, and improve financial performance. We expect the business to deliver a substantially improved performance over the medium term as our focus shifts to enhancing margins and return on capital.

 

 

 

About Carclo plc

Carclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a preferred and trusted partner of global customers, offering high-precision critical components that meet the needs of life sciences, aerospace, optics, and technology industries.

 

LEI: 21380078MEM399JPI956

 

Enquiries:

Carclo plc 01924 268040

Frank Doorenbosch - Chief Executive Officer

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZZGMDVFNGFZM
Date   Source Headline
26th Apr 20247:00 amRNSTrading Statement
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes
18th Oct 20227:00 amRNSTrading Update
13th Oct 20221:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.